Cargando…

The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics

AIMS: Classic Hodgkin lymphoma (cHL) should be distinguished from its wide variety of histological mimics, including reactive conditions and mature B and T cell neoplasms. Thymus and activation‐related chemokine (TARC) is produced in extremely high quantities by the Hodgkin/Reed–Sternberg (HRS) tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilsdonk, Melvin, Veldman, Carlijn, Rosati, Stefano, Plattel, Wouter, Diepstra, Arjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100154/
https://www.ncbi.nlm.nih.gov/pubmed/36345263
http://dx.doi.org/10.1111/his.14836
Descripción
Sumario:AIMS: Classic Hodgkin lymphoma (cHL) should be distinguished from its wide variety of histological mimics, including reactive conditions and mature B and T cell neoplasms. Thymus and activation‐related chemokine (TARC) is produced in extremely high quantities by the Hodgkin/Reed–Sternberg (HRS) tumour cells and is largely responsible for the attraction of CD4(+) T cells into the cHL tumour micro‐environment. In the current study we evaluated the diagnostic potential of TARC immunohistochemistry in daily practice in a tertiary referral centre in the Netherlands. METHODS AND RESULTS: A total of 383 cases, approximately half of which were cHL mimics, were prospectively evaluated in the period from June 2014 to November 2020. In 190 cHL cases, 92% were TARC‐positive and the majority of cases showed strong and highly specific staining in all HRS cells (77%). In most cases, TARC could discriminate between nodular lymphocyte‐predominant and lymphocyte‐rich Hodgkin lymphoma. HRS‐like cells in mature lymphoid neoplasms were rarely positive (6.4%) and there was no TARC staining at all in 64 reactive lymphadenopathies. CONCLUSIONS: TARC immunohistochemistry has great value in differentiating between cHL and its mimics, including nodular lymphocyte‐predominant Hodgkin lymphoma, reactive lymphadenopathies and mature lymphoid neoplasms with HRS‐like cells.